SymBio files bendamustine for lymphoma in Japan
This article was originally published in Scrip
Executive Summary
The Japanese bioventure SymBio Pharmaceuticals has filed for the approval in its home market of its lead product, bendamustine (SyB L-0501), for the treatment of refractory and relapsed low-grade non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma.